Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters









Publication year range
1.
Author Correction: Why Japan lacks a vibrant biotech industry.
Kessel, Mark; Vickrey, Chris.
Nat Biotechnol ; 42(7): 1150, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38834707
2.
Why Japan lacks a vibrant biotech industry.
Kessel, Mark; Vickrey, Chris.
Nat Biotechnol ; 42(5): 694, 2024 May.
Article in English | MEDLINE | ID: mdl-38649768

Subject(s)
Biotechnology , Japan , Humans , Drug Industry/economics
3.
How to fix tuberculosis R&D-the community speaks.
Kessel, Mark; Rana, Bhavana; Boehme, Catharina.
Nat Biotechnol ; 37(4): 350-351, 2019 04.
Article in English | MEDLINE | ID: mdl-30824862

Subject(s)
Tuberculosis/drug therapy , Tuberculosis/economics , Biotechnology/economics , Developing Countries/economics , Drug Development/economics , Humans , Public-Private Sector Partnerships/economics , Research/economics , Tuberculosis/epidemiology
4.
Ignore the Delaware director-compensation cases at your peril.
Lilienfeld, Doreen; Polovoy, Brian; Kessel, Mark.
Nat Biotechnol ; 34(4): 373-4, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27054986

Subject(s)
Biotechnology/economics , Biotechnology/legislation & jurisprudence , Drug Industry/economics , Drug Industry/legislation & jurisprudence , Delaware , Humans , Public Sector
5.
Preparing for crises.
Kessel, Mark; Masella, Robert.
Nat Biotechnol ; 34(2): 133-6, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26849512

Subject(s)
Decision Making , Drug Industry/organization & administration , Emergencies , Public Relations , Humans
6.
Why microbial diagnostics need more than money.
Kessel, Mark.
Nat Biotechnol ; 33(9): 898-900, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26348950

Subject(s)
Bacterial Infections/diagnosis , Bacterial Infections/economics , Bacterial Typing Techniques/methods , Drug Industry/economics , Drug Resistance, Microbial , Molecular Diagnostic Techniques/methods , Bacterial Infections/microbiology , United States
7.
What Ebola tells us about outbreak diagnostic readiness.
Perkins, Mark D; Kessel, Mark.
Nat Biotechnol ; 33(5): 464-9, 2015 May.
Article in English | MEDLINE | ID: mdl-25965752

Subject(s)
Disease Outbreaks , Hemorrhagic Fever, Ebola/epidemiology , Ebolavirus/pathogenicity , Hemorrhagic Fever, Ebola/diagnosis , Hemorrhagic Fever, Ebola/virology , Humans
8.
Diagnostics for hepatitis C: an urgent need for action.
Denkinger, Claudia M; Kessel, Mark.
Lancet Glob Health ; 3(4): e195, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25794673

Subject(s)
Hepatitis C/diagnosis , Serologic Tests , Algorithms , Hepacivirus/isolation & purification , Humans , Poverty Areas , Sensitivity and Specificity , Serologic Tests/economics , Serologic Tests/standards
9.
Restoring the pharmaceutical industry's reputation.
Kessel, Mark.
Nat Biotechnol ; 32(10): 983-90, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25299916

Subject(s)
Drug Industry , Public Opinion , Drug Industry/ethics , Drug Industry/legislation & jurisprudence , Drug Industry/organization & administration , Humans
10.
Diagnostics as the first line of defense in global health security.
Kessel, Mark.
Nat Biotechnol ; 32(6): 513-4, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24911488

Subject(s)
Communicable Disease Control/organization & administration , Communicable Diseases/diagnosis , Communicable Diseases/epidemiology , Disease Outbreaks/prevention & control , Disease Outbreaks/statistics & numerical data , Global Health , Population Surveillance/methods , Communicable Disease Control/methods , Humans
11.
Reducing the burden of disclosure for public biotech companies.
Evans, Robert; Kessel, Mark.
Nat Biotechnol ; 32(5): 419-20, 2014 May.
Article in English | MEDLINE | ID: mdl-24811509

Subject(s)
Biotechnology , Public Sector , Biotechnology/economics , Biotechnology/legislation & jurisprudence , Disclosure , Drug Industry/economics , Drug Industry/legislation & jurisprudence
12.
Neglected diseases, delinquent diagnostics.
Kessel, Mark.
Sci Transl Med ; 6(226): 226ed6, 2014 Mar 05.
Article in English | MEDLINE | ID: mdl-24598586

Subject(s)
Neglected Diseases/diagnosis , Neglected Diseases/therapy , Translational Research, Biomedical/trends , Communicable Disease Control , Global Health , Humans , Malaria/diagnosis , Malaria/therapy , Trypanosomiasis, African/diagnosis , Trypanosomiasis, African/therapy , Tuberculosis/diagnosis , Tuberculosis/therapy , United States , World Health Organization
13.
Do you really want to be a biotech board member?
Kessel, Mark.
Nat Biotechnol ; 31(12): 1072-4, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24316635

Subject(s)
Biotechnology/organization & administration , Governing Board/organization & administration , Job Description , Leadership
14.
Stock options and beyond.
Cannon, John J; Kessel, Mark.
Nat Biotechnol ; 31(8): 676-80, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23929334

Subject(s)
Drug Industry/economics , Investments , Drug Industry/legislation & jurisprudence , Humans , Investments/economics , Investments/legislation & jurisprudence , Taxes/economics , Taxes/legislation & jurisprudence
15.
Know before you go.
Kessel, Mark.
Nat Biotechnol ; 30(3): 219-20, 2012 Mar 07.
Article in English | MEDLINE | ID: mdl-22398611

Subject(s)
Biotechnology/economics , Industry/economics , Capital Financing , Drug Discovery/economics
16.
Sarbanes-Oxley overburdens biotech companies.
Kessel, Mark.
Nat Biotechnol ; 29(12): 1081-2, 2011 Dec 08.
Article in English | MEDLINE | ID: mdl-22158358

Subject(s)
Drug Industry/legislation & jurisprudence , Drug Industry/economics , Government Regulation , Humans , Investments , Small Business
17.
The problems with today's pharmaceutical business--an outsider's view.
Kessel, Mark.
Nat Biotechnol ; 29(1): 27-33, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21221096

Subject(s)
Biomedical Research/economics , Biotechnology/economics , Drug Industry/economics , Biomedical Research/trends , Biotechnology/trends , Drug Industry/trends , Drugs, Generic , Orphan Drug Production
18.
A lifeline for the biotech sector.
Kessel, Mark.
Nat Biotechnol ; 27(2): 123-4, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19204686

Subject(s)
Biotechnology/economics , Financing, Government , Private Sector/economics , Public Sector/economics , United States , United States Food and Drug Administration
19.
Other ways of financing your company.
Aldag, Jörn; Kessel, Mark; Ibrahim, Adrian; Hill, Ray; McCubbin, Paul.
Nat Biotechnol ; 26(2): 155-7, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18273945

ABSTRACT

The public markets aren't what they used to be and venture capitalists are seeking investments with shorter timelines. But the good news is several new sources of financing are becoming available.


Subject(s)
Biotechnology/economics , Capital Financing/economics , Entrepreneurship/economics , Industry/economics , Investments/economics , Internationality
20.
A better prescription for drug-development financing.
Kessel, Mark; Frank, Frederick.
Nat Biotechnol ; 25(8): 859-66, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17687358

Subject(s)
Capital Financing/organization & administration , Drug Design , Drug Industry/organization & administration , Investments/organization & administration , Models, Organizational , Pharmaceutical Preparations/economics , Research/organization & administration , United States
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL